Confirmation of the mantle-cell lymphoma International Prognostic Index in randomized trials of the European Mantle-Cell Lymphoma Network

Journal of Clinical Oncology

Volumn 32, Issue 13, 2014, Pages 1338-1346

  Hoster, Eva ^a,b   Klapper, Wolfram ^c   Hermine, Olivier ^g   Kluin Nelemans, Hanneke C ^j   Walewski, Jan ^l   Van Hoof, Achiel ^m   Trneny, Marek ⁿ   Geisler, Christian H ^o   Raimondo, Francesco Di ^p   Szymczyk, Michal ^l   Stilgenbauer, Stephan ^f   Thieblemont, Catherine ^h   Hallek, Michael ^e   Forstpointner, Roswitha ^a   Pott, Christiane ^d   Ribrag, Vincent ⁱ   Doorduijn, Jeanette ^k   Hiddemann, Wolfgang ^a   Dreyling, Martin H ^a   Unterhalt, Michael ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

^c UNIVERSITY OF KIEL   (Germany)

^d UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^e UNIVERSITY OF COLOGNE   (Germany)

^f UNIVERSITY OF ULM   (Germany)

^g UNIVERSITÉ PARIS DESCARTES   (France)

^h SAINT LOUIS HOSPITAL   (France)

ⁱ INSTITUT GUSTAVE ROUSSY   (France)

^j UNIVERSITY OF GRONINGEN   (Netherlands)

^k ERASMUS MC CANCER INSTITUTE   (Netherlands)

^l INSTITUTE OF ONCOLOGY   (Poland)

^m A Z Sint Jan AV   (Belgium)

ⁿ CHARLES UNIVERSITY   (Czech Republic)

^o University of Copenhagen   (Denmark)

^p UNIVERSITY OF CATANIA   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

LACTATE DEHYDROGENASE; ANTINEOPLASTIC AGENT; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; MONOCLONAL ANTIBODY; PREDNISONE; R CHOP PROTOCOL; R-CHOP PROTOCOL; RITUXIMAB; VINCRISTINE;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CONTROLLED STUDY; DRUG TREATMENT FAILURE; FEMALE; HAZARD RATIO; HIGH RISK POPULATION; HUMAN; HUMAN TISSUE; INTERMEDIATE RISK PATIENT; LACTATE DEHYDROGENASE BLOOD LEVEL; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MANTLE CELL LYMPHOMA; MANTLE CELL LYMPHOMA INTERNATIONAL PROGNOSTIC INDEX; MIDDLE AGED; OVERALL SURVIVAL; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TIME TO TREATMENT; VERY ELDERLY; CANCER STAGING; CHEMORADIOTHERAPY; COHORT ANALYSIS; METHODOLOGY; MULTICENTER STUDY (TOPIC); PATHOLOGY; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMORADIOTHERAPY; CISPLATIN; COHORT STUDIES; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; FEMALE; HUMANS; LYMPHOMA, MANTLE-CELL; MALE; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; NEOPLASM STAGING; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PREDNISONE; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; VINCRISTINE;

EID: 84902649810     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.52.2466     Document Type: Article

References (46)

1. Harris NL, Jaffe ES, Stein H, et al: A revised European-American classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group. Blood 84:1361-1392, 1994 (Pubitemid 24273002)
2. Swerdlow S, Campo E, Harris NL, et al: WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (International Agency for Research on Cancer, Lyon, France). Geneva, Switzerland, WHO, 2008
3. Zhou Y, Wang H, Fang W, et al: Incidence trends of mantle cell lymphoma in the United States between 1992 and 2004. Cancer 113:791-798, 2008
4. Herrmann A, Hoster E, Zwingers T, et al: Improvement of overall survival in advanced stage mantle cell lymphoma. J Clin Oncol 27:511-518, 2009
5. Hoster E, Dreyling M, Klapper W, et al: A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood 111:558-565, 2008
6. Hermine O, Hoster E, Walewski J, et al: Alternating courses of 3x CHOP and 3x DHAP plus rituximab followed by a high dose ARA-C containing myeloablative regimen and autologous stem cell transplantation (ASCT) is superior to 6 courses CHOP plus rituximab followed by myeloablative radiochemotherapy and ASCT in mantle cell lymphoma: Results of the MCL Younger Trial of the European Mantle Cell Lymphoma Network (MCL net). ASH Annual Meeting Abstracts 116:110, 2010
7. Hermine O, Hoster E, Walewski J, et al: Alternating courses of 3x CHOP and 3x DHAP plus rituximab followed by a high dose ARA-C containing myeloablative regimen and autologous stem cell transplantation (ASCT) increases overall survival when compared to 6 courses of CHOP plus rituximab followed by myeloablative radiochemotherapy and ASCT in mantle cell lymphoma: Final analysis of the MCL Younger Trial of the European Mantle Cell Lymphoma Network (MCL net). ASH Annual Meeting Abstracts 120:151, 2012
8. Kluin-Nelemans HC, Hoster E, Hermine O, et al: Treatment of older patients with mantle-cell lymphoma. N Engl J Med 367:520-531, 2012
9. Oken MM, Creech RH, Tormey DC, et al: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649-655, 1982 (Pubitemid 13149996)
10. Klapper W, Hoster E, Determann O, et al: Ki-67 as a prognostic marker in mantle cell lymphoma: Consensus guidelines of the pathology panel of the European MCL Network. J Hematop 2:103-111, 2009
11. Cheson BD, Horning SJ, Coiffier B, et al: Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 17:1244, 1999
12. Ahnn S, Anderson SJ: Sample size determination for comparing more than two survival distributions. Stat Med 14:2273-2282, 1995
13. Gray RJ: A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 16:1141-1154, 1988
14. Harrell FE, Califf RM, Pryor DB, et al: Evaluating the yield of medical tests. JAMA 247:2543-2546, 1982 (Pubitemid 12155954)
15. Cohen J: Weighted kappa: Nominal scale agreement with provision for scaled disagreement or partial credit. Psychol Bull 70:213-220, 1968
16. Budde LE, Guthrie KA, Till BG, et al: Mantle cell lymphoma international prognostic index but not pretransplantation induction regimen predicts survival for patients with mantle-cell lymphoma receiving high-dose therapy and autologous stem-cell transplantation. J Clin Oncol 29:3023-3029, 2011
17. Chang JE, Peterson C, Choi S, et al: VcR-CVAD induction chemotherapy followed by maintenance rituximab in mantle cell lymphoma: A Wisconsin Oncology Network study. Br J Haematol 155:190-197, 2011
18. Chiappella A, Puccini B, Ferrero S, et al: Retrospective analysis of 206 mantle cell lymphoma patients at diagnosis: Mantle Cell International Prognostic Index (MIPI) is a good predictor of death event in patients treated either with rituximab-chemotherapy or rituximab-high-dose-chemotherapy. ASH Annual Meeting Abstracts 116:1784, 2010
19. Damon LE, Johnson JL, Niedzwiecki D, et al: Immunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle-cell lymphoma: CALGB 59909. J Clin Oncol 27:6101-6108, 2009
20. Dong HJ, Zhou LT, Fang C, et al: TP53 mutation is not an independent prognostic factor in patients with mantle cell lymphoma at advanced stage. Med Oncol 29:2166-2173, 2011
21. Dunleavy K, Neelapu SS, Kwak LW, et al: Association of idiotype vaccine-induced T-cell response with improved survival and time-to-next treatment (TTNT) in untreated mantle cell lymphoma (MCL). J Clin Oncol 30, 2012 (suppl; abstr 2528)
22. Eve HE, Gambell J, Smith P, et al: The Simplified Mantle-Cell Lymphoma International Prognostic Index predicts overall survival but not progression-free survival in patients with mantle-cell lymphoma treated with fludarabine and cyclophosphamide +/- rituximab: Results of a randomized phase II trial. Leuk Lymphoma 50:1709-1711, 2009
23. Geisler CH, Kolstad A, Laurell A, et al: The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT). Blood 115:1530-1533, 2010
24. Gressin R, Caulet-Maugendre S, Deconinck E, et al: Evaluation of the (R)VAD+C regimen for the treatment of newly diagnosed mantle cell lymphoma: Combined results of two prospective phase II trials from the French GOELAMS group. Haematologica 95:1350-1357, 2011
25. Mato AR, Zielonka T, Feldman T, et al: The association between the Mantle Cell Lymphoma International Prognostic Index (MIPI) and survival in patients treated with rituximab-HCVAD (RHCVAD) alternating with rituximab-methotrexate- AraC (R-MTX-AraC). J Clin Oncol 28, 2010 (suppl; abstr 8092)
26. Merli F, Luminari S, Ilariucci F, et al: Rituximab plus HyperCVAD alternating with high dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma, a multicentre trial from Gruppo Italiano Studio Linfomi. Br J Haematol 156:346-353, 2012
27. Peterlin P, Leux C, Gastinne T, et al: Is ASCT with TBI superior to ASCT without TBI in mantle cell lymphoma patients? Transplantation 94:295-301, 2012
28. Raty R, Honkanen T, Jantunen E, et al: Prolonged immunochemotherapy with rituximab, cytarabine and fludarabine added to cyclophosphamide, doxorubicin, vincristine and prednisolone and followed by rituximab maintenance in untreated elderly patients with mantle cell lymphoma: A prospective study by the Finnish Lymphoma Group. Leuk Lymphoma 53:1920-1928, 2012
29. Romaguera JE, Fayad LE, Feng L, et al: Tenyear follow-up after intense chemoimmunotherapy with rituximab-HyperCVAD alternating with rituximab-high dose methotrexate/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma. Br J Haematol 150:200-208, 2010
30. Ruan J, Martin P, Furman RR, et al: Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma. J Clin Oncol 29:690-697, 2011
31. Salek D, Vasova I, Pytlik R, et al: Mantle cell lymphoma international prognostic score is valid and confirmed in unselected cohort of patients treated in rituximab era. ASH Annual Meeting Abstracts 112:3745, 2008
32. Salek D, Vesela P, Boudova L, et al: Retrospective analysis of 235 unselected patients with mantle cell lymphoma confirms prognostic relevance of Mantle Cell Lymphoma International Prognostic Index and Ki-67 in the era of rituximab: Long-term data from the Czech Lymphoma Project Database. Leuk Lymphoma [epub ahead of print on August 13, 2013]
33. Schaffel R, Hedvat CV, Teruya-Feldstein J, et al: Prognostic impact of proliferative index determined by quantitative image analysis and the International Prognostic Index in patients with mantle cell lymphoma. Ann Oncol 21:133-139, 2010
34. Shah BD, Cultrera JL, Sokol L, et al: Evaluation of the Mantle Cell Lymphoma International Prognostic Index (MIPI) as an indicator of overall survival, progression free survival, survival from relapse. ASH Annual Meeting Abstracts 116:5082, 2010
35. Smith SD, Hsi E, Bolwell B, et al: Validation of the Mantle Cell Lymphoma International Prognostic Index: A single-center retrospective analysis. Am J Hematol 85:454-456, 2010
36. Spurgeon SE, Pindyck T, Okada C, et al: Cladribine plus rituximab is an effective therapy for newly diagnosed mantle cell lymphoma. Leuk Lymphoma 52:1488-1494, 2011
37. Terol MJ, Teruel AI, Amat P, et al: Validation of the new prognostic index (MIPI) in mantle cell lymphoma: A single institution experience. Ann Oncol 19, 2008 (abstr 439)
38. Todorovic M, Balint B, Andjelic B, et al: Outcome prediction of advanced mantle cell lymphoma by international prognostic index versus different mantle cell lymphoma indexes: One institution study. Med Oncol 29:2212-2219, 2011
39. van 't Veer MB, de Jong D, MacKenzie M, et al: High-dose Ara-C and beam with autograft rescue in R-CHOP responsive mantle cell lymphoma patients. Br J Haematol 144:524-530, 2009
40. van de Schans SA, Janssen-Heijnen ML, Nijziel MR, et al: Validation, revision and extension of the Mantle Cell Lymphoma International Prognostic Index in a population-based setting. Haematologica 95:1503-1509, 2010
41. Ying ZT, Zheng W, Wang XP, et al: The clinical features, therapeutic responses, and prognosis of the patients with mantle cell lymphoma. Chin J Cancer 31:348-353, 2012
42. Dreyling M, Thieblemont C, Gallamini A, et al: ESMO Consensus conferences: Guidelines on malignant lymphoma-Part 2: Marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma. Ann Oncol 24:857-877, 2013
43. Royston P, Altman DG, Sauerbrei W: Dichotomizing continuous predictors in multiple regression: A bad idea. Stat Med 25:127-141, 2006 (Pubitemid 43136953)
44. Chiappella A, Frairia C, Puccini B, et al: Mantle Cell Lymphoma International Prognostic Index (MIPI) and Biological-MIPI are better predictors of the outcome of mantle cell lymphoma (MCL) patients than IPI: A retrospective analysis. Haematologica 94:395, 2009 (abstr 0981)
45. de Jong D, Rosenwald A, Chhanabhai M, et al: Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: Validation of tissue microarray as a prerequisite for broad clinical applications: A study from the Lunenburg Lymphoma Biomarker Consortium. J Clin Oncol 25:805-812, 2007 (Pubitemid 350002880)
46. Martin P, Chadburn A, Christos P, et al: Outcome of deferred initial therapy in mantle-cell lymphoma. J Clin Oncol 27:1209-1213, 2009